Overview

What is Ipamorelin + CJC-1295?

Ipamorelin and CJC-1295 are two peptides that work together through complementary biological pathways to support your body’s natural growth hormone production. Rather than introducing synthetic hormones from outside, this combination works with your body’s own pituitary gland — encouraging it to produce and release growth hormone in a more natural, pulsatile pattern.

Think of it this way — your body already has the machinery to produce growth hormone. This combination simply helps that machinery work more effectively.

Ipamorelin is a selective growth hormone secretagogue — a compound that signals the pituitary gland to release growth hormone. What makes Ipamorelin stand out is its remarkable selectivity — it stimulates growth hormone release without triggering unwanted hormonal side effects like elevated cortisol or prolactin associated with earlier peptides.

CJC-1295 is a growth hormone-releasing hormone (GHRH) analogue — working through a completely different receptor pathway, mimicking the body’s own GHRH signal to further support pulsatile growth hormone release.

Together they work synergistically — activating two separate and complementary pathways simultaneously for a greater combined effect than either peptide alone.

Mechanism

How does the combination work?

Your body’s growth hormone system operates on a delicate balance of signals — stimulating hormones that tell the pituitary to release GH, and inhibiting hormones that tell it to stop.

• CJC-1295 activates the GHRH receptor — mimicking the body’s natural growth hormone releasing hormone signal and priming the pituitary for GH release.
• Ipamorelin simultaneously activates the ghrelin receptor (GHSR-1a) — providing a second, complementary signal through a completely separate pathway.
• Synergistic release — When both receptors are activated at the same time, the resulting GH release is greater than either peptide could produce individually. This dual-pathway approach more closely replicates the robust, natural GH pulses associated with deep sleep and youthful endocrine function.

Growth hormone pulses are typically observed within 15 to 30 minutes following administration.

Applications

What can Ipamorelin + CJC-1295 support?

• Sleep quality & overnight recovery — The largest natural pulses of growth hormone occur during deep sleep. This combination is commonly used before bed to support the body’s overnight regenerative processes and enhance recovery while you rest.
• Lean body composition — Growth hormone plays a key role in protein synthesis and the maintenance of lean muscle tissue. Supporting natural GH production may help maintain lean body composition when combined with appropriate diet and exercise.
• Recovery & regeneration — By supporting the body’s natural GH signaling, this combination may assist in the recovery and repair processes that occur after physical activity.
• IGF-1 support — Growth hormone stimulates the production of Insulin-like Growth Factor 1 (IGF-1) in the liver — an important anabolic signaling molecule that plays a role in muscle maintenance, cellular repair, and overall metabolic health.
• Energy & vitality — Supporting healthy growth hormone levels is associated with improved energy, mood, and overall sense of vitality — particularly relevant as natural GH production declines with age.

Format

Why a dissolving strip?

Traditional Ipamorelin and CJC-1295 protocols require subcutaneous injection — needles, syringes, reconstitution, refrigeration, and precise dosing calculations. Our dissolving strip format eliminates all of that complexity.

• Fast-dissolving — place on your tongue and it absorbs in seconds
• Zero needles — no injections, no syringes, no mixing
• No refrigeration required — stable and travel-friendly
• Pharmaceutical-grade quality
• Pre-measured for convenience
• Discreet and portable — fits in any bag or pocket

Evidence

What does the research say?

The combination of a GHRH analogue and a selective GH secretagogue is supported by a clear pharmacological rationale — dual pathway stimulation producing synergistic GH release has been documented in preclinical and early clinical research.

• Ipamorelin’s selectivity — Specifically engineered to stimulate GH release without the off-target hormonal effects of earlier peptides. Studies confirmed it does not cause significant increases in cortisol or prolactin — even at doses far above its effective GH-stimulating dose.
• Anti-catabolic effects — Preclinical research demonstrated Ipamorelin’s ability to counteract glucocorticoid-induced muscle wasting and bone loss in animal models — suggesting a role in preserving muscle tissue during catabolic conditions.
• Bone & muscle support — Animal studies showed Ipamorelin increased bone mineral content and supported lean tissue maintenance — consistent with the known effects of growth hormone on musculoskeletal health.
• Synergistic GH release — The combination of a GHRH analogue and a ghrelin receptor agonist produces supra-additive GH release — a greater combined effect than either compound alone — supporting a more robust and physiologically relevant GH pulse.

Note: The majority of research on Ipamorelin and CJC-1295 has been conducted in preclinical animal models and limited early-phase human studies. These peptides are not FDA-approved for anti-aging, body composition, or performance purposes. Our strips are intended as a wellness supplement only. Consult your healthcare provider before starting any new supplement protocol.

Usage

Best practices for use

• Timing — Before bed on an empty stomach for best results. Growth hormone release can be blunted by elevated blood glucose — avoid taking after a high-carbohydrate meal.
• Consistency — Regular, consistent use is key to supporting the body’s GH signaling over time.
• Monitoring — Consider periodic monitoring of IGF-1 levels and general metabolic markers with your healthcare provider.

Safety

Is it safe?

Ipamorelin has demonstrated a favorable safety profile compared to earlier growth hormone secretagogues — its selectivity means it does not trigger the unwanted cortisol and prolactin responses associated with older compounds.

• Not approved by the FDA for human clinical use
• Not suitable for individuals with active malignancy, pituitary tumors, or diabetic retinopathy
• Not suitable for pregnant or breastfeeding individuals
• Not suitable for those under 18 years of age
• Prohibited by WADA for competitive athletes
• Long-term safety data in humans is limited
• Always consult your healthcare provider before starting this or any peptide protocol

FAQ

Frequently asked questions